Glioblastoma Therapy with Substance P labelled with Bismuth-213

Gliomas are the most frequent primary brain tumors in adult patients. The most malignant of them – glioblastoma multiforme (GBM), is characterized by the worst prognosis with a median survival of 15 months. The infiltrating character of the tumor, molecular heterogeneity, as well as the protective effects of blood-brain barrier are the main causes of insufficient front line treatments (surgery, radio and chemotherapy); 90% of patients have a recurrence at the original tumor location. Therefore a new type of treatment strategies is urgently needed. Because the majority of recurrences occur within 2 cm of the resection margin, local therapies are currently under investigation. Riva P et al. in 1995 have proposed local treatment of malignant gliomas (1). This method allows for a higher concentration of drug into the tumor and omitting the blood-brain barrier. This method is also suitable for local administration of radiopharmaceuticals. Different types of biologically active ligands and radioisotopes were used.

KROLICKI Leszek;  KUNIKOWSKA Jolanta;  KOZIARA H;  MORGENSTERN Alfred;  BRUCHERTSEIFER Frank;  JAKUCINSKI M;  PAWLAK Dariusz;  MIKOŁAJCZAK Renata;  KROLICKI B;  BARSZCZ Slawomir; 

2013-04-30

Medknow

JRC79497

1450-1147,   

http://www.journalonweb.com/wjnm,    https://publications.jrc.ec.europa.eu/repository/handle/JRC79497,